Bristol-Myers Squibb CompanyBMYNYSE
LOADING
|||
R&D Expense Growth Accelerating
Trending higher, above historical average, slight contraction.
Left:
||||
Year-over-year research & development expense growth
Latest
11.76%
↑ 139% above average
Average (39q)
4.92%
Historical baseline
Range
High:96.42%
Low:-47.76%
CAGR
-4.4%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 11.76% |
| Q2 2025 | 1.16% |
| Q1 2025 | -19.80% |
| Q4 2024 | 18.49% |
| Q3 2024 | 2.53% |
| Q2 2024 | -14.81% |
| Q1 2024 | 8.80% |
| Q4 2023 | 13.68% |
| Q3 2023 | -3.54% |
| Q2 2023 | -1.87% |
| Q1 2023 | -8.33% |
| Q4 2022 | 6.36% |
| Q3 2022 | 1.68% |
| Q2 2022 | 4.55% |
| Q1 2022 | -14.84% |
| Q4 2021 | -19.78% |
| Q3 2021 | -0.64% |
| Q2 2021 | 47.08% |
| Q1 2021 | -20.29% |
| Q4 2020 | 11.78% |
| Q3 2020 | 0.52% |
| Q2 2020 | 7.21% |
| Q1 2020 | 16.50% |
| Q4 2019 | 45.96% |
| Q3 2019 | 4.05% |
| Q2 2019 | 0.69% |
| Q1 2019 | -4.27% |
| Q4 2018 | 7.61% |
| Q3 2018 | -47.76% |
| Q2 2018 | 96.42% |
| Q1 2018 | -12.83% |
| Q4 2017 | -4.60% |
| Q3 2017 | 35.94% |
| Q2 2017 | 6.56% |
| Q1 2017 | -15.90% |
| Q4 2016 | 6.68% |
| Q3 2016 | -10.11% |
| Q2 2016 | 11.44% |
| Q1 2016 | -40.71% |
| Q4 2015 | 69.26% |